Holen Sie sich die Stockscreener-App
3.76
1.35%
0.05
Handel nachbörslich:
3.69
-0.07
-1.86%
Schlusskurs vom Vortag:
$3.71
Offen:
$3.96
24-Stunden-Volumen:
161.44K
Relative Volume:
0.82
Marktkapitalisierung:
$33.92M
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-9.85M
KGV:
-2.7197
EPS:
-1.3825
Netto-Cashflow:
$-6.62M
1W Leistung:
+32.86%
1M Leistung:
+14.63%
6M Leistung:
-11.53%
1J Leistung:
-32.98%
1-Tages-Spanne:
$3.65
$4.00
1-Wochen-Bereich:
$2.972
$4.50
52-Wochen-Spanne:
$2.72
$6.92
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.76 | 33.92M | 7.50M | -9.85M | -6.62M | -1.3825 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Maxim Group | Buy |
| 2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion A S Adr Aktie (EVAX) Neueste Nachrichten
EVAX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Reports No RevenueEstimate Dispersion - www.dars.gov.et
POM Stock Price, Quote & News - Syfe
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeInstitutional Sentiment - https://www.siam.in/
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeLeveraged ETF Flow - dars.gov.et
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Evaxion A/S (EVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evaxion A/SAmerican Depositary Share (NQ: EVAX - The Chronicle-Journal
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion (EVAX) taps investors with new ADS sale - Stock Titan
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Raises Questions on Cash BurnEarnings Sentiment Score - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentRevenue Beat Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentOperating Margin Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentGAAP Earnings Report - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentNew Analyst Coverage - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentMid-Term Outlook - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateMcClellan Summation - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateRisk Parity Rebalance - www.dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateGamma Flip Level - dars.gov.et
Evaxion Biotech Earnings Call: Data Strength, Cash Strain - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
EVAX Q1 2026 Earnings: Wider-than-Expected Loss of -$0.50 Per Share as Pre-Revenue Biotech Advances PipelineLow Estimate Range - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceInside Day Breakout - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceLiquidity Sweep - dars.gov.et
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceWatchlist Stock Ideas - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsChaikin Flow - careplusvn.com
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDip Buy Trade - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDiagonal Spread Trade - dars.gov.et
Evaxion (EVAX) Edges Higher as Support Holds, Resistance LoomsTrading Ideas - dars.gov.et
Evaxion Biotech A/S Adr (EVAX) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewswire Inc.
Evaxion (EVAX) Dips 1.25% as Stock Tests Support Near $3.01TICK Divergence - dars.gov.et
European ADRs Rose As Biopharma Names Led The Pack - Finimize
US-Traded European Stocks Slipped As Arm And ArcelorMittal Fell - Finimize
Evaxion A/S Sponsored ADR Actuals & Estimates (NASDAQ:EVAX) - TradingView
Evaxion receives Prix Galien UK Award for Best digital health solution - Finansavisen
European ADRs Edged Higher As Biotech Led Friday’s Moves - Finimize
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewswire Inc.
European ADRs Started The Week In The Green - Finimize
European ADRs Edged Higher In US Trading - Finimize
EVAXEvaxion A/S ADR Options - Finviz
EVAX - Finviz
Evaxion Biotech Signals Strong R&D Momentum Amid Cash Constraints - TipRanks
Most VolatileStock ScreenerNews - Finviz
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - GlobeNewswire Inc.
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - Finansavisen
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma - GlobeNewswire Inc.
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Finansavisen
Evaxion concludes Annual General Meeting - Finansavisen
Finanzdaten der Evaxion A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):